Heroin Addiction and Related
Clinical Problems 2010; 12(1):5-16
Evaluation of
Opioid-Dependent Prisoners in Oral Opioid Maintenance
Therapy
Metz V., Matzenauer
C., Kammerer K., Winklbaur B., Ebner N., Radler D., Fischer G.
Correspondence: Prof. Gabriele
Fischer, Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Waehringer Guertel 18-20 - 1090 Vienna, Austria
Phone: +43 1 40400 2117; Fax:
+43 1 40400 3629; E-mail: gabriele.fischer@meduniwien.ac.at
Summary: Background: Opioid maintenance treatment is available in prison
in many countries, but without a specific methodology or homogeneity. The aim
of our study was to investigate characteristics and differences among
opioid-dependent prisoners in an Austrian penitentiary. Methods: Structured
assessments were obtained from 57 (78.1%) of 73 opioid-maintained prisoners on
their demographic data, imprisonment terms, health status and quality of life.
Results: From 1996 until 2007, the number of opioid-maintained detainees
increased by 444%. Prisoners treated with methadone had significantly more
convictions (p=0.036) and a longer duration of polydrug abuse (p=0.093) and
opioid consumption (p=0.05) than patients maintained on slow-release morphine.
Conclusions: There is a strong need for a diversification of opioid maintenance
treatments, as well as the development of a specific methodology for the use of
therapeutic opioids in prison.
Publication Type: Regular
article
Heroin Addiction and Related
Clinical Problems 2010; 12(1):17-24
Dose Determination
in Dual Diagnosed Heroin Addicts during Methadone Treatment
Maremmani I.,
Pacini M., Canoniero S., Deltito J., Maremmani A. G. I., Tagliamonte A.
Correspondence: Icro Maremmani,
MD; Vincent P. Dole Dual Diagnosis Unit, Santa Chiara University Hospital,
Department of Psychiatry, University of Pisa, Via Roma, 67 56100 PISA, Italy,
EU. Phone +39 0584 790073 Fax +39 0584 72081 E-Mail: maremman@med.unipi.it
Summary: Ninety-nine consecutive responders to treatment for heroin
addiction (54 with one or more Axis I psychiatric diagnosis (DD-patients), and
45 without psychiatric comorbidity (NDD-patients), were monitored prospectively
(20 months on average, min.1, max. 51), in order to achieve some useful
clinical information pertaining to effective methadone dose determination for
double diagnosed heroin addicts. First day and first month dosages do not
differ between the two groups. Stabilization dosages are higher in DD patients
than in NDD patients. The time to reach stabilization phase is longer in DD
patients than in NDD patients. Tapering of methadone follows a similar trend in
both groups. DD patients need more attention from clinicians, especially when
stabilization dosage has to be established.
Publication Type: Regular
article
Heroin Addiction and Related
Clinical Problems 2010; 12(1):25-32
Urine Labelling
Marker System for Drug Testing Improves Patient Compliance
Simojoki K., Alho
A.
Correspondence: Hannu Alho,
Ph.D., M.D.; National Institute of Health and Welfare, Department of Mental
Health and Substance Abuse Services. POB 30, 00271 Helsinki, Finland
Phone: +358-20-6108123 Fax:
+358-20-6108133 E-mail: hannu.alho@thl.fi
Summary: Urine drug testing plays an important role in substance abuse
treatments. When strictly controlled, as it often is, urine sampling creates a
humiliating situation and ties up resources. A new sample labelling method has
been developed to make supervision unnecessary. This innovation is achieved by
labelling the urine with polyethylene glycols. In this study, 57 patients who
required urine sampling were randomized into two groups, the traditional
supervised (TS) group and the new marker (NM) group. The urine test return rate
was 98.3% in the NM group and 100% in the TS group. Attempts to manipulate the
urine samples were discovered in 2% of the NM group and 0% of the TS group. Most
patients preferred the NM testing method. The personnel too preferred the NM
system, and estimated that it reduced their workload dedicated to drug
screening by 50%. We conclude that the NM method is more acceptable to patients
and personnel, and may increase compliance as a result.
Publication Type: Regular
Article
Heroin Addiction and Related
Clinical Problems 2010; 12(1):33-36
Quality of Life As a Means
of Assessing Outcome in Opioid Dependence Treatment
Torrens M.
Correspondence: Marta Torrens
MD, Drug Addiction Unit, IAPS-Hospital del Mar, Barcelona, Universitat Autònoma
de Barcelona, Barcelona, Spain, E-mail mtorrens@imas.imim.es
Summary: Not available
Publication Type: Letter to
the editor
Heroin Addiction and Related
Clinical Problems 2010; 12(1):37-40
Why There Has Been an
Excess of Overdoses in Norway Since 1990?
Haraldsen M.
Correspondence: Martin
Haraldsen, Rodslia 12, 3222 Sandefjord, Norway
E-mail: mar.har@c2i.net
Summary: Not available
Publication Type: